DNA vaccines: Developing new strategies against cancer

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Fioretti, Daniela ^a   Iurescia, Sandra ^a   Fazio, Vito Michele ^b,c   Rinaldi, Monica ^a  

^a CNR   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; CANCER VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 70; LIVE VACCINE; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; TETANUS TOXIN; TUMOR ANTIGEN;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNIZATION; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; COST EFFECTIVENESS ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLUENZA; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY CARCINOMA; LARGE SCALE PRODUCTION; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOMA; MALARIA; MELANOMA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PLASMID; PROSTATE CANCER; REVIEW; TUMOR IMMUNITY; UTERINE CERVIX CANCER; IMMUNOLOGY;

CANCER VACCINES; HUMANS; NEOPLASMS; VACCINES, DNA;

EID: 77951695279     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/174378     Document Type: Review

References (149)

1. Hoption Cann S. A., Van Netten J. P., Van Netten C., Dr William Coley and tumour regression: a place in history or in the future Postgraduate Medical Journal 2003 79 938 672 680 (Pubitemid 38134682)
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P., Estimates of the cancer incidence and mortality in Europe in 2006 Annals of Oncology 2007 18 3 581 592 (Pubitemid 46359643)
3. Varmus H., The new era in cancer research Science 2006 312 5777 1162 1165 (Pubitemid 43801131)
4. Wolff J. A., Malone R. W., Williams P., Direct gene transfer into mouse muscle in vivo Science 1990 247 4949 1465 1468 (Pubitemid 20145055)
5. Ulmer J. B., Donnelly J. J., Parker S. E., Heterologous protection against influenza by injection of DNA encoding a viral protein Science 1993 259 5102 1745 1749 (Pubitemid 23114660)
6. Wang B., Ugen K. E., Srikantan V., Gene inoculation generates immune responses against human immunodeficiency virus type 1 Proceedings of the National Academy of Sciences of the United States of America 1993 90 9 4156 4160 (Pubitemid 23134185)
7. Raz E., Carson D. A., Parker S. E., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses Proceedings of the National Academy of Sciences of the United States of America 1994 91 20 9519 9523 (Pubitemid 24297946)
8. Donnelly J. J., Ulmer J. B., Shiver J. W., Liu M. A., DNA vaccines Annual Review of Immunology 1997 15 617 648 (Pubitemid 27169294)
9. Haupt K., Roggendorf M., Mann K., The potential of DNA vaccination against tumor-associated antigens for antitumor therapy Experimental Biology and Medicine 2002 227 4 227 237
10. Yannelli J. R., Wroblewski J. M., On the road to a tumor cell vaccine: 20 years of cellular immunotherapy Vaccine 2004 23 1 97 113
11. George A. J., Stevenson F. K., Prospects for the treatment of B cell tumors using idiotypic vaccination International Reviews of Immunology 1989 4 4 271 310
12. Van der Bruggen P., Zhang Y., Chaux P., Tumor-specific shared antigenic peptides recognized by human T cells Immunological Reviews 2002 188 51 64 (Pubitemid 35398865)
13. Stevenson F. K., Rice J., Zhu D., Tumor vaccines Advances in Immunology 2004 82 49 103 (Pubitemid 38209510)
14. Caballero O. L., Chen Y.-T., Cancer/testis (CT) antigens: potential targets for immunotherapy Cancer Science 2009 100 11 2014 2021
15. Wang R.-F., Rosenberg S. A., Human tumor antigens for cancer vaccine development Immunological Reviews 1999 170 85 100 (Pubitemid 29490747)
16. Disis M. L., Cheever M. A., HER-2/neu oncogenic protein: issues in vaccine development Critical Reviews in Immunology 1998 18 1-2 37 45
17. Berinstein N. L., Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review Journal of Clinical Oncology 2002 20 8 2197 2207
18. Robbins P. F., El-Gamil M., Kawakami Y., Rosenberg S. A., Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy Cancer Research 1994 54 12 3124 3126 (Pubitemid 24208914)
19. Kawakami Y., Eliyahu S., Delgado C. H., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 3515 3519 (Pubitemid 24139460)
20. Kawakami Y., Eliyahu S., Delgado C. H., Identification of a human melanoma antigen recognized by tumor- infiltrating lymphocytes associated with in vivo tumor rejection Proceedings of the National Academy of Sciences of the United States of America 1994 91 14 6458 6462 (Pubitemid 24984961)
21. Doehn C., Bohmer T., Kausch I., Sommerauer M., Jocham D., Prostate cancer vaccines: current status and future potential BioDrugs 2008 22 2 71 84 (Pubitemid 351414750)
22. Cheever M. A., Allison J. P., Ferris A. S., The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research Clinical Cancer Research 2009 15 17 5323 5337
23. Webster R. G., Robinson H. L., DNA vaccines: a review of developments BioDrugs 1997 8 4 273 292
24. Liu M. A., Ulmer J. B., Human clinical trials of plasmid DNA vaccines Advances in Genetics 2005 55 25 40
25. Porgador A., Irvine K. R., Iwasaki A., Barber B. H., Restifo N. P., Germain R. N., Predominant role for directly transfected dendritic cells in antigen presentation to CD 8 + T cells after gene gun immunization Journal of Experimental Medicine 1998 188 6 1075 1082 (Pubitemid 28443331)
26. Fu T.-M., Ulmer J. B., Caulfield M. J., Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes Molecular Medicine 1997 3 6 362 371
27. Torres C. A. T., Iwasaki A., Barber B. H., Robinson H. L., Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations Journal of Immunology 1997 158 10 4529 4532 (Pubitemid 127483769)
28. Dupuis M., Denis-Mize K., Woo C., Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice Journal of Immunology 2000 165 5 2850 2858
29. Haddad D., Ramprakash J., Sedegah M., Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles Journal of Immunology 2000 165 7 3772 3781
30. Chattergoon M. A., Robinson T. M., Boyer J. D., Weiner D. B., Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells Journal of Immunology 1998 160 12 5707 5718
31. Anderson R. J., Schneider J., Plasmid DNA and viral vector-based vaccines for the treatment of cancer Vaccine 2007 25 supplement 2 B24 B34
32. Gurunathan S., Klinman D. M., Seder R. A., DNA vaccines: immunology, application, and optimization Annual Review of Immunology 2000 18 927 974
33. Drake C. G., Jaffee E., Pardoll D. M., Mechanisms of immune evasion by tumors Advances in Immunology 2006 90 51 81
34. Seliger B., Strategies of tumor immune evasion BioDrugs 2005 19 6 347 354
35. Lowe D. B., Shearer M. H., Jumper C. A., Kennedy R. C., Towards progress on DNA vaccines for cancer Cellular and Molecular Life Sciences 2007 64 18 2391 2403
36. Gregorevic P., Blankinship M. J., Chamberlain J. S., Viral vectors for gene transfer to striated muscle Current Opinion in Molecular Therapeutics 2004 6 5 491 498
37. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 2003 302 5644 415 419
38. Fazio V. M., Ria F., Franco E., Immune response at birth, long-term immune memory and 2 years follow-up after in-utero anti-HBV DNA immunization Gene Therapy 2004 11 6 544 551
39. Rinaldi M., Signori E., Rosati P., Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety Vaccine 2006 24 21 4586 4591
40. MacGregor R. R., Boyer J. D., Ugen K. E., First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response Journal of Infectious Diseases 1998 178 1 92 100
41. Mincheff M., Tchakarov S., Zoubak S., Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial European Urology 2000 38 2 208 217
42. Le T. P., Coonan K. M., Hedstrom R. C., Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers Vaccine 2000 18 18 1893 1901
43. Smith H. A., Regulation and review of DNA vaccine products Developments in Biologicals 2000 104 57 62
44. Cui Z., DNA vaccine Advances in Genetics 2005 54 257 289
45. Wolff J., Lewis D. L., Herweijer H., Hegge J., Hagstrom J., Non-viral approaches for gene transfer Acta Myologica 2005 24 3 202 208
46. Buchan S., Grnevik E., Mathiesen I., King C. A., Stevenson F. K., Rice J., Electroporation as a prime/boost strategy for naked DNA vaccination against a tumor antigen Journal of Immunology 2005 174 10 6292 6298
47. Rice J., Ottensmeier C. H., Stevenson F. K., DNA vaccines: precision tools for activating effective immunity against cancer Nature Reviews Cancer 2008 8 2 108 120
48. Rinaldi M., Fioretti D., Iurescia S., Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model Biochemical and Biophysical Research Communications 2008 370 2 279 284
49. Roos A.-K., Eriksson F., Timmons J. A., Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment PLoS ONE 2009 4 9, article e7226
50. Brave A., Hallengard D., Gudmundsdotter L., Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen Vaccine 2009 27 28 3692 3696
51. Trimble C., Lin C.-T., Hung C.-F., Comparison of the CD 8 + T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe Vaccine 2003 21 25-26 4036 4042
52. Lou P.-J., Cheng W.-F., Chung Y.-C., Cheng C.-Y., Chiu L.-H., Young T.-H., PMMA particle-mediated DNA vaccine for cervical cancer Journal of Biomedical Materials Research, Part A 2009 88 4 849 857
53. Quaak S. G. L., van den Berg J. H., Toebes M., GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial European Journal of Pharmaceutics and Biopharmaceutics 2008 70 2 429 438
54. Chan R. C.-F., Gutierrez B., Ichim T. E., Lin F., Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma Oncology Reports 2009 22 5 1197 1203
55. Settelen N., Roch O., Bock D., Rooke R., Braun S., Meyer O., Controlled plasmid gene transfer to murine renal carcinoma by hexadecylphosphocholine Journal of Controlled Release 2004 94 1 237 244
56. Timmerman J. M., Singh G., Hermanson G., Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma Cancer Research 2002 62 20 5845 5852
57. Rosenberg S. A., Yang J. C., Sherry R. M., Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen Human Gene Therapy 2003 14 8 709 714
58. Todorova K., Ignatova I., Tchakarov S., Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded Cancer Immunity 2005 5 1
59. Miller A. M., Ozenci V., Kiessling R., Pisa P., Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer Journal of Immunotherapy 2005 28 4 389 395
60. Meng W. S., Butterfield L. H., Ribas A., -fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination Cancer Research 2001 61 24 8782 8786
61. McNeel D. G., Dunphy E. J., Davies J. G., Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer Journal of Clinical Oncology 2009 27 25 4047 4054
62. Perales M.-A., Yuan J., Powel S., Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma Molecular Therapy 2008 16 12 2022 2029
63. Biragyn A., Kwak L. W., Models for lymphoma Current Protocols in Immunology 2002 chapter 20 unit 20.6
64. Low L., Mander A., McCann K., DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer Human Gene Therapy 2009 20 11 1269 1278
65. Mander A., Chowdhury F., Low L., Ottensmeier C. H., Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines Cancer Immunology, Immunotherapy 2009 58 5 789 800
66. Takeshita F., Tanaka T., Matsuda T., Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity Journal of Virology 2006 80 13 6218 6224
67. Trimble C. L., Peng S., Kos F., A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3 Clinical Cancer Research 2009 15 1 361 367
68. Lu Y., Ouyang K., Fang J., Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope Vaccine 2009 27 39 5411 5418
69. Smith C. L., Dunbar P. R., Mirza F., Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence International Journal of Cancer 2005 113 2 259 266
70. Montgomery D. L., Donnelly J. J., Shiver J. W., Liu M. A., Ulmer J. B., Protein expression in vivo by injection of polynucleotides Current Opinion in Biotechnology 1994 5 5 505 510 (Pubitemid 24321418)
71. Dean D. A., Strong D. D., Zimmer W. E., Nuclear entry of nonviral vectors Gene Therapy 2005 12 11 881 890
72. Weide B., Garbe C., Rammensee H.-G., Pascolo S., Plasmid DNA- and messenger RNA-based anti-cancer vaccination Immunology Letters 2008 115 1 33 42 (Pubitemid 350298588)
73. Neelapu S. S., Kwak L. W., Vaccine therapy for B-cell lymphomas: next-generation strategies Hematology 2007 2007 1 243 249
74. Hoebe K., Jiang Z., Tabeta K., Genetic analysis of innate immunity Advances in Immunology 2006 91 175 226 (Pubitemid 44308345)
75. Tudor D., Dubuquoy C., Gaboriau V., Lefvre F., Charley B., Riffault S., TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines Vaccine 2005 23 10 1258 1264 (Pubitemid 40126529)
76. Saha S., Takeshita F., Matsuda T., Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine Journal of Immunology 2007 179 2 1147 1154
77. Morgan D. J., Kreuwel H. T. C., Sherman L. A., Antigen concentration and precursor frequency determine the rate of CD 8 + T cell tolerance to peripherally expressed antigens Journal of Immunology 1999 163 2 723 727
78. Sandberg J. K., Franksson L., Sandberg J., T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity Journal of Immunology 2000 165 1 25 33 (Pubitemid 30429486)
79. Berzofsky J. A., Epitope selection and design of synthetic vaccines. Molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines Annals of the New York Academy of Sciences 1993 690 256 264
80. Rammensee H.-G., Friede T., Stevanovic S., MHC ligands and peptide motifs: first listing Immunogenetics 1995 41 4 178 228
81. Ruppert J., Sidney J., Celis E., Kubo R. T., Grey H. M., Sette A., Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules Cell 1993 74 5 929 937 (Pubitemid 23270612)
82. Mok H., Lee S., Wright D. W., Crowe J. E. Jr., Enhancement of the CD 8 + T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope Vaccine 2008 26 37 4775 4782
83. Berzofsky J. A., Ahlers J. D., Belyakov I. M., Strategies for designing and optimizing new generation vaccines Nature Reviews Immunology 2001 1 3 209 219 (Pubitemid 33741959)
84. Leitner W. W., Bergmann-Leitner E. S., Hwang L. N., Restifo N. P., Type I Interferons are essential for the efficacy of replicase-based DNA vaccines Vaccine 2006 24 24 5110 5118
85. Leifert J. A., Rodriguez-Carreno M. P., Rodriguez F., Whitton J. L., Targeting plasmid-encoded proteins to the antigen presentation pathways Immunological Reviews 2004 199 40 53 (Pubitemid 38736763)
86. Janssen E. M., Lemmens E. E., Wolfe T., Christen U., Von Herrath M. G., Schoenberger S. P., CD 4 + T cells are required for secondary expansion and memory in CD 8 + T lymphocytes Nature 2003 421 6925 852 856 (Pubitemid 36254145)
87. Stevenson F. K., Rice J., Ottensmeier C. H., Thirdborough S. M., Zhu D., DNA fusion gene vaccines against cancer: from the laboratory to the clinic Immunological Reviews 2004 199 156 180 (Pubitemid 38736770)
88. Stevenson F. K., Ottensmeier C. H., Johnson P., DNA vaccines to attack cancer Proceedings of the National Academy of Sciences of the United States of America 2004 101 supplement 2 14646 14652 (Pubitemid 39346737)
89. Wang R., Doolan D. L., Le T. P., Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine Science 1998 282 5388 476 480
90. Calarota S., Bratt G., Nordlund S., Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients Lancet 1998 351 9112 1320 1325
91. Graham B. S., Koup R. A., Roederer M., Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine Journal of Infectious Diseases 2006 194 12 1650 1660
92. Greenland J. R., Letvin N. L., Chemical adjuvants for plasmid DNA vaccines Vaccine 2007 25 19 3731 3741
93. DellAgnola C., Biragyn A., Clinical utilization of chemokines to combat cancer: the double-edged sword Expert Review of Vaccines 2007 6 2 267 283
94. Rinaldi M., Ria F., Parrella P., Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients tumor cells Cancer Research 2001 61 4 1555 1562
95. Calarota S. A., Weiner D. B., Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants Immunological Reviews 2004 199 84 99
96. Zhu D., Stevenson F. K., DNA gene fusion vaccines against cancer Current Opinion in Molecular Therapeutics 2002 4 1 41 48
97. Stevenson F. K., Rice J., Optimizing cancer immunotherapy trials: back to basics European Journal of Immunology 2006 36 5 1070 1073
98. Keene J. A., Forman J., Helper activity is required for the in vivo generation of cytotoxic T lymphocytes Journal of Experimental Medicine 1982 155 3 768 782
99. Von Herrath M. G., Yokoyama M., Dockter J., Oldstone M. B. A., Whitton J. L., CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge Journal of Virology 1996 70 2 1072 1079
100. Elia L., Mennuni C., Storto M., Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: initial identification of predictive biomarkers European Journal of Immunology 2006 36 5 1337 1349
101. Lu S., Wang S., Grimes-Serrano J. M., Current progress of DNA vaccine studies in humans Expert Review of Vaccines 2008 7 2 175 191
102. Stopeck A. T., Hersh E. M., Akporiaye E. T., Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma Journal of Clinical Oncology 1997 15 1 341 349
103. Drape R. J., Macklin M. D., Barr L. J., Jones S., Haynes J. R., Dean H. J., Epidermal DNA vaccine for influenza is immunogenic in humans Vaccine 2006 24 21 4475 4481
104. Egan M. A., Megati S., Roopchand V., Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice Vaccine 2006 24 21 4510 4523
105. Luckay A., Sidhu M. K., Kjeken R., Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques Journal of Virology 2007 81 10 5257 5269
106. Ahlen G., Soderholm J., Tjelle T., In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD 3 + T cells Journal of Immunology 2007 179 7 4741 4753
107. Murtaugh M. P., Foss D. L., Inflammatory cytokines and antigen presenting cell activation Veterinary Immunology and Immunopathology 2002 87 3-4 109 121
108. Liu J., Kjeken R., Mathiesen I., Barouch D. H., Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation Journal of Virology 2008 82 11 5643 5649 (Pubitemid 351705271)
109. Bins A. D., Jorritsma A., Wolkers M. C., A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression Nature Medicine 2005 11 8 899 904 (Pubitemid 41161124)
110. Kelleher A. D., Puls R. L., Bebbington M., A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1 AIDS 2006 20 2 294 297
111. Webster D. P., Dunachie S., McConkey S., Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers Vaccine 2006 24 15 3026 3034
112. Egan M. A., Chong S. Y., Megati S., Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus AIDS Research and Human Retroviruses 2005 21 7 629 643
113. Wang R., Epstein J., Charoenvit Y., Induction in humans of CD 8 + and CD 4 + T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein Journal of Immunology 2004 172 9 5561 5569 (Pubitemid 38542058)
114. Wang S., Kennedy J. S., West K., Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers Vaccine 2008 26 8 1098 1110
115. Schneider J., Gilbert S. C., Hannan C. M., Induction of CD 8 + T cells using heterologous prime-boost immunisation strategies Immunological Reviews 1999 170 29 38
116. Schneider J., Gilbert S. C., Blanchard T. J., Enhanced immunogenicity for CD 8 + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara Nature Medicine 1998 4 4 397 402
117. Estcourt M. J., Ramsay A. J., Brooks A., Thomson S. A., Medveckzy C. J., Ramshaw I. A., Prime-boost immunization generates a high frequency, high-avidity CD 8 + cytotoxic T lymphocyte population International Immunology 2002 14 1 31 37
118. Degano P., Schneider J., Hannan C. M., Gilbert S. C., Hill A. V. S., Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD 8 + T cell immunogenicity and protective efficacy in the influenza and malaria models Vaccine 1999 18 7-8 623 632
119. Sica A., Bronte V., Altered macrophage differentiation and immune dysfunction in tumor development Journal of Clinical Investigation 2007 117 5 1155 1166
120. Curiel T. J., Tregs and rethinking cancer immunotherapy Journal of Clinical Investigation 2007 117 5 1167 1174
121. Collison L. W., Workman C. J., Kuo T. T., The inhibitory cytokine IL-35 contributes to regulatory T-cell function Nature 2007 450 7169 566 569
122. Munn D. H., Mellor A. L., Indoleamine 2,3-dioxygenase and tumor-induced tolerance Journal of Clinical Investigation 2007 117 5 1147 1154
123. Emens L. A., Reilly R. T., Jaffee E. M., Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocrine-Related Cancer 2005 12 1 1 17
124. Zou W., Immunosuppressive networks in the tumour environment and their therapeutic relevance Nature Reviews Cancer 2005 5 4 263 274
125. Xiang R., Luo Y., Niethammer A. G., Reisfeld R. A., Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis Immunological Reviews 2008 222 1 117 128
126. Niethammer A. G., Xiang R., Becker J. C., A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth Nature Medicine 2002 8 12 1369 1375
127. Kaplan C. D., Kruger J. A., Zhou H., Luo Y., Xiang R., Reisfeld R. A., A novel DNA vaccine encoding PDGFR suppresses growth and dissemination of murine colon, lung and breast carcinoma Vaccine 2006 24 47-48 6994 7002
128. Sumida S. M., McKay P. F., Truitt D. M., Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines Journal of Clinical Investigation 2004 114 9 1334 1342
129. Steitz J., Bruck J., Lenz J., Knop J., Tuting T., Depletion of CD 25 + CD 4 + T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon -induced, CD 8 + T-cell-dependent immune defense of B16 melanoma Cancer Research 2001 61 24 8643 8646
130. Sutmuller R. P. M., Van Duivenvoorde L. M., Van Elsas A., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD 25 + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses Journal of Experimental Medicine 2001 194 6 823 832
131. Grauer O. M., Nierkens S., Bennink E., CD 4 + FoxP 3 + regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglionia immune responses in vivo International Journal of Cancer 2007 121 1 95 105
132. Chen A., Liu S., Park D., Kang Y., Zheng G., Depleting intratumoral CD 4 + CD 25 + regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer Cancer Research 2007 67 3 1291 1298
133. Knutson K. L., Dang Y., Lu H., IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice Journal of Immunology 2006 177 1 84 91
134. Dannull J., Su Z., Rizzieri D., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells Journal of Clinical Investigation 2005 115 12 3623 3633
135. Mahnke K., Schonfeld K., Fondel S., Depletion of CD 4 + CD 25 + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro International Journal of Cancer 2007 120 12 2723 2733
136. Curiel T. J., Coukos G., Zou L., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004 10 9 942 949
137. Li B., Lalani A. S., Harding T. C., Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy Clinical Cancer Research 2006 12 22 6808 6816
138. Ruter J., Barnett B. G., Kryczek I., Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines Frontiers in Bioscience 2009 14 1761 1770
139. Ledwith B. J., Manam S., Troilo P. J., Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice Intervirology 2000 43 46 258 272
140. Sheets R. L., Stein J., Manetz T. S., Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts Toxicological Sciences 2006 91 2 610 619 (Pubitemid 43827313)
141. Bagarazzi M. L., Boyer J. D., Javadian M. A., Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees Journal of Medical Primatology 1997 26 1-2 27 33
142. Hawkins R. E., Zhu D., Ovecka M., Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines Blood 1994 83 11 3279 3288
143. Johnson L. E., Frye T. P., Arnot A. R., Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) Vaccine 2006 24 3 293 303
144. Tagawa S. T., Lee P., Snively J., Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma Cancer 2003 98 1 144 154
145. Weber J., Boswell W., Smith J., Phase 1 trial of intranodal injection of a melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma Journal of Immunotherapy 2008 31 2 215 223
146. Kim D., Gambhira R., Karanam B., Generation and characterization of a preventive and therapeutic HPV DNA vaccine Vaccine 2008 26 3 351 360
147. Rinaldi M., Iurescia S., Fioretti D., Ponzetto A., Carloni G., Strategies for successful vaccination against hepatocellular carcinoma International Journal of Immunopathology and Pharmacology 2009 22 2 269 277
148. Disis M. L., Schiffman K., Guthrie K., Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine Journal of Clinical Oncology 2004 22 10 1916 1925
149. Coleman S., Clayton A., Mason M. D., Jasani B., Adams M., Tabi Z., Recovery of CD 8 + T-cell function during systemic chemotherapy in advanced ovarian cancer Cancer Research 2005 65 15 7000 7006